You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
McKesson
Johnson and Johnson
Medtronic
Boehringer Ingelheim

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

DURYSTA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

US ANDA Litigation and Generic Entry Outlook for Durysta

A generic version of DURYSTA was approved as bimatoprost by APOTEX INC on December 1st, 2014.

  Start Trial

Summary for DURYSTA
International Patents:169
US Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Drug Prices: Drug price information for DURYSTA
DailyMed Link:DURYSTA at DailyMed
Drug patent expirations by year for DURYSTA
Drug Prices for DURYSTA

See drug prices for DURYSTA

Pharmacology for DURYSTA

US Patents and Regulatory Information for DURYSTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial   Start Trial
Allergan Inc DURYSTA bimatoprost IMPLANT;OPHTHALMIC 211911-001 Mar 4, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DURYSTA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0660716 SPC/GB02/035 United Kingdom   Start Trial PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716 02C0033 France   Start Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716 C300099 Netherlands   Start Trial PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
AstraZeneca
Colorcon
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.